Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2025

Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)

Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559

Macaluso FS,

Grova M,

Bossa F,

Sorge A,

Festa S,

Onali S,

Orlando A; Italian Group for the study of Inflammatory Bowel Diseases (IG-IBD)

In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.

Keywords:

October 2024

Risankizumab for Ulcerative Colitis Two Randomized Clinical Trials

JAMA. 2024;332:881-897 doi: 10.1001/jama.2024.12414

Louis E,

Wu K,

Chen S,

Cheng L,

Shu L,

Duan WR,

Louis et al. demonstrated risankizumab to significantly improve clinical remission rates compared to placebo in both an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis.